

MORBIDITY AND MORTALITY

WEEKLY REPORT

- 845 Pesticide-Related Illnesses Associated with the Use of a Plant Growth Regulator
- 847 Vaccination Coverage Among Children Enrolled in Head Start Programs and Licensed Child Care Centers and Entering School — United States and Selected Reporting Areas
- 855 Update: Outbreak of Poliomyelitis Dominican Republic and Haiti
 857 Weekly Update: West Nile Virus
 - Activity United States

Pesticide-Related Illnesses Associated with the Use of a Plant Growth Regulator — Italy, 2001

During January–February 2001, eight cases of acute illness in the county of Ragusa, Italy, were reported to the Italian National Institute for Health (INIH) by the Milan Poison Control Center (MPCC) and were attributed to exposure to Dormex[®], a plant growth regulator with hydrogen cyanamide as the active ingredient. These cases were identified during a pilot project for acute pesticide-related illness surveillance. Subsequent active case finding at health-care clinics by the Ragusa Occupational Health Unit identified six additional cases. MPCC identified nine cases in other areas of Italy. Of the 23 cases of acute illness, 22 resulted from occupational exposure during mixing and/or applying of Dormex[®], and one was from unintentional ingestion. This report summarizes the investigation of these cases, which implicates a pesticide as the causative agent and demonstrates the usefulness of surveillance for detecting pesticide-related illnesses.

All 22 workers were male with a median age of 41 years (range: 16–76 years). It is not known whether personal protection equipment was used. Eighteen of the workers reported dermatologic manifestations, including macular or papular rash (11), erythema/ hyperemia (nine), pruritus (two), and caustic burns to the hand (two). Two workers reported eye irritation. Fourteen workers had systemic signs and/or symptoms characteristic of adverse effects of the active ingredient, including tachycardia (four), weakness (four), dizziness (four), palpitations (three), headache (three), vomiting and/or nausea (three), dyspnea (three), and hypotension (one). Of 21 persons initially treated in an emergency department, 12 (52%) were hospitalized; one person was treated by a local physician. Thirteen patients had low severity effects (i.e., minimal effects that rapidly resolved), and nine had moderate severity effects (i.e., nonlife threatening effects that are more pronounced, prolonged, or of a systemic nature) (CDC, unpublished data, 2001).

The nonoccupational case occurred in a man aged 44 years who unintentionally ingested the product that had been placed in a plastic water bottle in the refrigerator. He became seriously ill with third degree shock, coma, miosis, and hepatic necrosis and required care in an intensive care unit.

In May 2001, INIH notified the Italian Ministry of Health (IMH) about the outbreak. IMH, which acts as the regulatory agency for pesticides and agricultural products, suspended use of the product in Italy.

Pesticide-Related Illnesses — Continued

Reported by: F Davanzo, L Faraoni, Milan Poison Control Center; G Miceli, M Conticello, L Bongiovanni, Ragusa Occupational Health Unit; T Ballard, L Settimi, M Rubbiani, I Marcello, S Bascherini, Italian National Institute of Health. L Mehler, MD, California Dept of Pesticide Regulation, Sacramento. Surveillance Br, Div of Surveillance, Hazard Evaluations, and Field Studies, National Institute for Occupational Safety and Health, CDC.

Editorial Note: This report describes the adverse health effects of hydrogen cyanamide, the active ingredient in Dormex[®], which is a plant growth regulator designed to stimulate more uniform budbreak following dormancy, resulting in more uniform flowering and maturity at harvest. Dormex[®] is applied by nebulization with an atomizer. Adverse health effects from contact with hydrogen cyanamide include severe irritation and ulceration of the eyes, skin, and respiratory tract (1,2). It also inhibits aldehyde dehydrogenase and can produce the acetaldehyde syndrome (e.g., vomiting, parasympathetic hyperactivity, dyspnea, hypotension, tachycardia, and confusion) when exposure coincides with alcohol use (2).

Hydrogen cyanamide is classified in the European Union as "toxic" if swallowed, "harmful" in contact with skin, "irritating" to eyes and skin, and capable of producing sensitization after skin contact. The U.S. Environmental Protection Agency (EPA) places both the active ingredient (hydrogen cyanamide) and the product (Dormex®), which contains 50% hydrogen cyanamide, into the acute toxicity category I (danger)*. The Dormex® product label provided by the manufacturer to EPA indicates that the following personal protective equipment must be used by applicators and other handlers of this product: chemical-resistant suit, chemical-resistant gloves, chemical-resistant footwear, eye and face protection, and a respirator with either an organic vapor-removing cartridge with a prefilter approved for pesticides or a canister approved for pesticides.

On the basis of experimental trials of the product, Dormex[®] was classified in Italy as "harmful" if swallowed, "harmful" in contact with the skin, "irritating" to the eyes and skin, capable of causing serious damage to the eyes, and of causing sensitization after skin contact. This corresponds to EPA acute toxicity category II. The product sold in Italy was for use only by licensed applicators and required wearing suitable protective clothing, gloves, and eye and face protection.

Since 1981, only five cases of acute pesticide-related illness associated with hydrogen cyanamide have been identified in the United States (CDC, unpublished data, 2001). All five patients were exposed in California. No cases were identified in the other seven states with acute pesticide-related illness surveillance programs or by the Toxic Exposure Surveillance System, which collects poisoning reports submitted by approximately 85% of U.S. poison control centers. The low number of U.S. cases compared with Italy may be related to greater precautions required by the label of the U.S.-distributed product.

The findings in this report are subject to at least two limitations. First, because active surveillance for acute pesticide-related illness cases was conducted in Ragusa only, patients who sought health care in other parts of Italy may have been missed. Second, lack of detailed information on the events surrounding exposure may have precluded identification of additional risk factors for hydrogen cyanamide-related illness.

^{*}EPA classifies all pesticide products into one of four acute toxicity categories based on established criteria (40 CFR Part 156). Pesticides with the greatest toxicity are in category I, and those with the least are in category IV.

Pesticide-Related Illnesses — Continued

Although use of Dormex[®] in Italy began in 2000, only three cases of acute illness associated with this product were identified by MPCC in 2000 (i.e., before establishment of the pilot surveillance program). One occurred in Ragusa and the other two were from other regions in southern Italy. These data suggest that fewer cases occurred in 2000 compared with 2001. Because emergency department medical records in Ragusa for 2000 were not available to the Occupational Health Unit, the total number of Ragusa cases that occurred in 2000 is unknown. The establishment of the pilot surveillance system in January 2001 probably enabled the detection of this outbreak through active case-finding and the use of a standardized form. Ragusa was selected for this pilot program, in part, because it is an area characterized by greenhouse cultivation of fruits and vegetables with extensive use of pesticides and because of heightened awareness of pesticide-related illnesses by the Ragusa Occupational Health Unit.

These findings demonstrate the usefulness of surveillance for detecting emerging pesticide problems (3). In addition, this outbreak suggests the need for international uniformity in both the acute toxicity category assigned to a pesticide and in the detailed recommendations and requirements provided on the pesticide label.

References

- 1. Grant WM. Toxicology of the eye. 3rd ed. Springfield, Illinois: Charles C. Tomas, 1986.
- Hathaway GJ, Proctor NH, Hughes JP. Proctor and Hughes' chemical hazards in the workplace. 4th ed. New York, New York: Van Nostrand Reinnold, 1996.
- 3. Thacker SB, Stroup DF, Parrish RG, Anderson HA. Surveillance in environmental public health. Am J Public Health 1996;86:633–8.

Vaccination Coverage Among Children Enrolled in Head Start Programs and Licensed Child Care Centers and Entering School — United States and Selected Reporting Areas, 1999–2000 School Year

Undervaccinated children enrolled in child care centers (1) and schools (2) are vulnerable to outbreaks of vaccine-preventable disease. One of the national health objectives for 2010 is to maintain \geq 95% vaccination coverage among children attending licensed child care centers and kindergarten through postsecondary school (objective 14-23) (3). To identify children who have not been vaccinated in compliance with state law, all states, five large cities (Chicago, Houston, New York, Philadelphia, and San Antonio), and eight territories conduct annual vaccination assessment surveys of coverage with basic vaccines among children enrolled in the Head Start program, enrolled in licensed child care centers, and entering kindergarten or first grade. These survey results are aggregated and analyzed by CDC to estimate national vaccination coverage. This report summarizes estimated coverage with the basic vaccines: ≥3 doses of poliovirus vaccine, \geq 3 tetanus containing doses (diphtheria and tetanus toxoids and acellular pertussis vaccine [DTaP]), diphtheria and tetanus toxoids (DT), or tetanus toxoids (Td), and 1 dose each of measles, mumps, and rubella vaccines for the September 1999–June 2000 school year. Results indicate that among reporting programs, the mean coverage for all vaccines was \geq 95% for the surveyed population. However, coverage varied from state to state, and approximately 30% of states did not submit reports. High rates of vaccination coverage must be maintained to prevent transmission of vaccinepreventable disease. States should conduct yearly assessments to maintain these rates among preschool- and school-aged children.

Because state and territorial laws determine vaccine and dosage requirements for child care and school attendance (4), methods of assessing vaccination coverage, sampling procedures, and data abstraction methods varied among the 64 participating vaccination programs. Overall mean coverage levels were estimated by weighting vaccine-specific coverage levels reported by each program to the birth cohort in the program area. Data were combined for all programs that reported coverage levels for kindergarten and/or first grade.

The 50 states, eight territories, five cities, and the District of Columbia (4) have vaccination programs that report findings of school-based surveys to CDC annually. During the reporting period, the 64 programs used a one page form that provided a line for reporting the proportion of children who received each of the basic antigens: \geq 3 doses of DTaP/DT/Td, \geq 3 doses of poliovirus vaccine, and 1 dose each of measles, mumps, and rubella vaccines.

Kindergarten/First Grade

Of the 64 programs, 44 (68.8%) submitted vaccination coverage levels for children enrolled in kindergarten and/or first grade (Table 1). The mean level among programs was 97.3% for poliovirus vaccine (range: 85.6%–99.9%), 97.2% for DTaP/DT/Td (range: 85.3%–99.9%), 97.1% for measles (range: 86%–100%), and 97.4% for mumps and rubella vaccines (range: 86%–100%); 38 (86.4%) programs reached the 2010 goal of \geq 95% coverage for poliovirus vaccine and measles, mumps, and rubella vaccines, and 37 (84.1%) reached the goal for DTaP/DT/Td.

Head Start Programs

Of the 64 programs, 44 (68.8%) submitted vaccination coverage levels for children enrolled in Head Start (Table 2). The mean level among programs was 96.7% for poliovirus vaccine (range: 85%–100%), 96.6% for DTaP/DT/Td (range: 83.9%–100%), and 96.8% for measles, mumps, and rubella (range: 80%–100%) vaccines. The number of programs that reached ≥95% coverage was 36 (81.8%) for poliovirus vaccine, 28 (63.6%) for DTaP/DT/Td, and 37 (84.1%) for measles, mumps, and rubella vaccines.

Licensed Child Care Centers

Of the 64 programs, 42 (65.6%) submitted vaccination coverage levels for children enrolled in child care (Table 3). The mean level among programs was 94.6% for poliovirus vaccine (range: 75%–99.8%), 95.5% for DTaP/DT/Td (range: 76%–100%), 94.7% for measles vaccine (range: 74%–99.9%), 94.8% for mumps vaccine (range: 74%–99.9%), and 94.8% for rubella vaccine (range: 74%–99.9%); 20 (47.6%) programs reached \geq 95% coverage for poliovirus vaccine, 23 (54.8%) for DTaP/DT/Td, and for mumps and rubella vaccines, and 22 (52.4%) for measles vaccine.

Reported by: Assessment Br, Data Management Div, National Immunization Program; and an EIS Officer, CDC.

Editorial Note: Since 1980, national coverage for recommended childhood vaccines among children entering school has been >90% (5). Although the incidence of vaccine-preventable disease is at an all-time low, coverage from >90% to >95% is considered necessary to prevent transmission of measles in secondary schools (5).

Although national coverage remained >95% for children entering kindergarten or first grade and children enrolled in Head Start during the 1999–2000 school year, state-specific coverage levels varied, especially among children in licensed child care; these

	%	% Population	%	%	%
Reporting area	Grade*	assessed†	Poliovirus [®]	DTaP/DT/Td [¶]	M/M/R**
United States					
(weighted mean)			97.3	97.2	97.1/97.4/97.4
New England					
Connecticut	K-12	_	_		_
Maine ^{tt §§} ¶¶	К	_	88.0	88.0	88.0
Massachusetts	К	98.4	97.2	97.3	98.0
New Hampshire***	1	_	99.6	99.5	98.4
Rhode Island***	K	90.3	98.7	98.2	96.9
Vermont ^{***}	K-1	97.0	96.2	97.1	91.4
Middle Atlantic					
New York State	К	100.0	98.8	98.8	97.2/98.6/98.6
New York City	К	100.0	98.2	98.5	96.4/98.5/98.4
New Jersey	_	_	_	_	
Pennsylvania	_	_	_	_	_
Philadelphia	K-1	6.1	91.0	91.0	91.0
East North Central					
Illinois	K-12	_			_
Chicago	_	_	_		_
Indiana	K-12	_	_	_	_
Michigan	К	100.0	98.8	99.0	99.2
Ohio	К	100.0	96.0	95.0	98.0
Wisconsin	К	1.1	95.8	96.6	94.3
West North Central					
lowa	К	100.0	95.0	90.0	98.0
Kansas***	K-2	_			
Minnesota	_	_	_	_	_
Missouri	К	_	97.7	97.1	97.3/99.1/99.1
Nebraska	К	100.0	97.3	97.5	96.2
North Dakota		—	—		—
South Dakota	К	100.0	98.0	98.8	98.7
South Atlantic					
Delaware	К	100.0	85.6	85.3	86.0
District of Columbia	PreK, K-1	100.0	93.6	94.2	95.8
Florida	K	3.0	99.0	99.1	98.8
Georgia	—	—	—		—
Maryland	К	95.1	99.8	99.7	98.5/99.8/99.7
North Carolina***	K-1	93.2	99.7	99.6	99.7
South Carolina***	K	9.5	99.0	99.0	100.0
Virginia	К	2.7	90.0	94.0	87.0
West Virginia	К	100.0	98.5	98.8	99.9

TABLE 1. Estimated vaccination coverage among children in kindergarten and first grade, by reporting area and vaccine — 64 vaccination programs, United States and selected territories, 1999-2000 school year

* Coverage estimates are from states that reported data for children entering kindergarten and/or first grade only. ⁺ The proportion of eligible children included in the assessment survey.

⁴ At least 3 doses of poliovirus vaccine unless otherwise indicated.
 ⁴ At least 3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), diphtheria and tetanus toxoids (DT), or tetanus toxoid (Td) unless otherwise indicated.

** One dose of measles vaccine, 1 dose of mumps vaccine, and 1 dose of rubella vaccine. Each antigen reported separately unless otherwise indicated.

^{††} At least 4 doses of poliovirus vaccine. ^{§§} At least 5 doses of DTaP, DT, or Td.

¹¹ At least 2 doses of measles, 2 doses of mumps, and 2 doses of rubella vaccines.

*** Measles, mumps, and rubella coverage reported for combined measles, mumps, and rubella vaccine (MMR). One dose of MMR unless otherwise indicated.

^{†††} Two doses of MMR.

^{\$\$\$} At least 4 doses of DTaP, DT, or Td.

United States and selec			-2000 Scho	Ul year	
	%	% Population	%	%	%
Reporting area	^{7₀} Grade*	assessed [†]		DTaP/DT/Td [¶]	% M/M/R**
East South Central					
Alabama	_	_	_	_	_
Kentucky***	К	99.7	96.0	97.0	96.0
Mississippi	1	100.0	99.2	99.2	99.2
Tennessee	К	100.0	98.5	98.5	98.5
West South Central					
Arkansas	_	_	97.0	98.0	99.0
Louisiana	K-1	100.0	97.0	98.6	98.9
Oklahoma	K	88.2	97.5	96.5	97.4
Texas	K-12				_
Houston		_	_		_
San Antonio	_	_	_	_	_
Mountain					
Arizona	K-1	99.2	97.3	98.0	98.2
Colorado	_	_	_	_	_
Idaho	PreK, K	_	96.6	95.1	97.2
Montana	K-1	100.0	99.1	98.9	99.1
Nevada	1	100.0	98.8	98.2	98.8
New Mexico	K-1	73.0	96.0	96.0	96.0
Utah	К	99.8	96.6	95.8	96.4/96.7/96.8
Wyoming	К	100.0	97.5	95.3	96.0
Pacific					
Alaska***	K-1	87.0	96.0	96.0	95.9
California ^{¶¶ §§§}	К	99.2	97.1	96.3	96.4
Hawaii	К	99.5	99.9	99.9	100.0
Oregon	K-1	99.0	96.7	96.0	97.6
Washington	K-1	100.0	95.0	95.0	98.0
Territories					
American Samoa	K-1	95.0	94.0	88.0	95.7
Guam		_	_	_	_
Marshall Islands		_	_	_	_
Micronesia		_	—		_
Northern Mariana Island		—	—	—	—
Palau	1	100.0	95.0	95.0	97.0
Puerto Rico	К	93.0	97.0	97.0	97.0
Virgin Islands	—	—	—	—	—
No. achieving ≥95%					
coverage goal			38	37	38

TABLE 1. (Continued) Estimated vaccination coverage among children in kindergarten and first grade, by reporting area and vaccine — 64 vaccination programs, United States and selected territories, 1999-2000 school year

* Coverage estimates are from states that reported data for children entering kindergarten and/or first grade only. ¹ The proportion of eligible children included in the assessment survey. ³ At least 3 doses of poliovirus vaccine unless otherwise indicated.

¹ At least 3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), diphtheria and tetanus toxoids (DT), or tetanus toxoid (Td) unless otherwise indicated.

** One dose of measles vaccine, 1 dose of mumps vaccine, and 1 dose of rubella vaccine. Each antigen reported separately unless otherwise indicated.
 ^{1†} At least 4 doses of poliovirus vaccine.
 ^{§§} At least 5 doses of DTaP, DT, or Td.
 ^{§§} At least 2 doses of DTaP, DT, or Td.

11 At least 2 doses of measles, 2 doses of mumps, and 2 doses of rubella vaccines.

*** Measles, mumps, and rubella coverage reported for combined measles, mumps, and rubella vaccine (MMR). One dose of MMR unless otherwise indicated.

^{\$\$\$} At least 4 doses of DTaP, DT, or Td.

	%			
Reporting area	Population assessed*	% Poliovirus⁺	% DTaP/DT/Td⁵	% M/M/R [¶]
	assesseu	TONOVITUS		
United States				
(weighted mean)		96.7	96.6	96.8
New England				
Connecticut				
Maine	77.0	96.0	96.0	96.0
Massachusetts	99.9	99.3	98.9	99.4
New Hampshire**		100.0	97.6	100.0
Rhode Island**	100.0	98.8	97.0	99.3
Vermont	100.0	89.2	88.3	91.1
Middle Atlantic				
New York State	100.0	98.7	98.7	98.4
New York City	100.0	99.3	99.4	99.5
New Jersey	—	_	_	—
Pennsylvania		—	—	—
Philadelphia		—	—	—
East North Central				
Illinois	56.3	97.0	97.5	97.9
Chicago		—	—	—
Indiana		96.0	94.0	97.0
Michigan	100.0	97.1	97.9	98.3
Ohio ^{††}	—	97.0	94.0	99.0
Wisconsin	98.8	86.6	83.9	89.0
West North Central				
lowa	61.0	99.0	97.0	98.0
Kansas**	12.0	100.0	99.0	99.0
Minnesota		—	—	—
Missouri		98.3	94.8	98.1
Nebraska		—	—	—
North Dakota		—	—	—
South Dakota	98.6	95.3	91.3	96.1
South Atlantic				
Delaware	100.0	87.0	92.0	83.0
District of Columbia	100.0	94.3	95.6	96.2
Florida	11.7	96.8	97.9	97.7
Georgia	_	_	_	_
Maryland	_	—	—	—
North Carolina**	37.7	97.6	98.2	97.8
South Carolina		—	—	—
Virginia	15.0	91.0	94.0	86.0
West Virginia	100.0	98.7	98.9	97.5

TABLE 2. Estimated vaccination coverage among children enrolled in Head Start programs, by reporting area and vaccine — 64 vaccination programs, United States and selected territories, 1999–2000 school year

* The proportion of eligible children included in the assessment survey.

⁴ At least 3 doses of poliovirus vaccine unless otherwise indicated.
 ⁵ At least 3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), diphtheria and tetanus toxoids (DT), or tetanus toxoid (Td) unless otherwise indicated.

¹ One dose of measles vaccine, 1 dose of mumps vaccine, and 1 dose of rubella vaccine. Each antigen reported separately unless otherwise indicated.

** Measles, mumps, and rubella coverage reported for combined measles, mumps, and rubella vaccine (MMR). One dose of MMR unless otherwise indicated.
 ^{+†} At least 4 doses of DTaP, DT, or Td.

	%	c '	e,	c /
Reporting area	Population assessed*	% Poliovirus⁺	% DTaP/DT/Td⁵	% M/M/R [¶]
East South Central				
Alabama	_	_	_	_
Kentucky	83.0	98.0	97.0	98.0
, Mississippi	2.7	99.6	99.7	99.6
Tennessee	95.7	99.7	99.5	99.3
West South Central				
Arkansas	54.0	97.0	92.0	99.0
Louisiana	100.0	85.0	93.0	80.0
Oklahoma		_	_	_
Texas	_		_	_
Houston	_		_	_
San Antonio	_	_	_	—
Mountain				
Arizona	99.1	98.3	99.5	99.5
Colorado	_	_	_	_
Idaho	_	96.4	92.7	95.8
Montana	_	100.0	99.9	100.0
Nevada	100.0	97.7	98.9	99.4
New Mexico	18.0	90.0	93.0	80.0
Utah	79.9	98.2	96.9	99.1
Wyoming	100.0	96.7	94.6	96.2
Pacific				
Alaska**	76.6	96.1	90.4	97.9
California	99.2	98.8	99.0	99.1
Hawaii	100.0	99.6	99.9	99.8
Oregon	100.0	97.2	97.7	98.0
Washington	98.0	99.0	100.0	99.0
Territories				
American Samoa	100.0	99.5	91.8	99.0
Guam	_	_	_	_
Marshall Islands	_	_	_	_
Micronesia	_	_	_	_
Northern Mariana	a			
Islands	100.0	94.0	94.0	92.0
Palau	100.0	96.0	96.0	96.0
Puerto Rico	99.0	97.0	96.0	98.0
Virgin Islands	100.0	100.0	100.0	100.0
No. achieving <u>></u> 9	5%			
coverage goal		36	28	37

TABLE 2. (Continued) Estimated vaccination coverage among children enrolled in Head Start programs, by reporting area and vaccine — 64 vaccination programs, United States and selected territories, 1999–2000 school year

* The proportion of eligible children included in the assessment survey.

⁴ At least 3 doses of poliovirus vaccine unless otherwise indicated.
 ⁵ At least 3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), diphtheria and tetanus toxoids (DT), or tetanus toxoid (Td) unless otherwise indicated.
 ¹ One dose of measles vaccine, 1 dose of mumps vaccine, and 1 dose of rubella vaccine. Each antigen reported and the pertus to a set of the pertus diverse dive

separately unless otherwise indicated. ** Measles, mumps, and rubella coverage reported for combined measles, mumps, and rubella vaccine (MMR). One dose of MMR unless otherwise indicated.

⁺⁺ At least 4 doses of DTaP, DT, or Td.

	%			
	Population	%	%	%
Reporting area	assessed*	Poliovirus [†]	DTaP/DT/Td⁵	M/M/R [¶]
United States				
(weighted mean)		94.6	95.5	94.7/94.8/94.8
New England				
Connecticut **	100.0	98.0	97.0	99.0
Maine	34.0	75.0	76.0	74.0
Massachusetts	90.6	97.9	97.3	98.0
New Hampshire ⁺⁺	_	96.3	94.9	95.4
Rhode Island ⁺⁺	_	97.2	96.1	97.1
Vermont	100.0	77.9	81.2	79.2
Middle Atlantic				
New York State	100.0	96.8	97.4	96.8/96.9/96.9
New York City	100.0	95.1	96.5	94.9/95.0/95.0
New Jersey	_	_	_	
Pennsylvania	_		_	_
Philadelphia	7.7	89.0	93.0	85.0
East North Central				
Illinois	46.6	92.7	94.1	93.2/93.1/93.2
Chicago	_	_	_	
Indiana	_	90.0	88.0	89.0/93.0/93.0
Michigan	100.0	93.8	96.4	93.4
Ohio**	51.9	98.0	97.0	98.0
Wisconsin	67.5	86.2	88.0	86.5
West North Central				
lowa	81.0	93.0	91.0	92.0
Kansas ^{††}	15.0	87.0	94.0	94.0
Minnesota	_	_	—	_
Missouri	_	97.0	93.3	97.0
Nebraska	_	_	_	_
North Dakota	_	_	_	_
South Dakota	76.7	96.3	94.0	96.1
South Atlantic				
Delaware	2.4	86.0	92.0	83.0
District of Columbia	100.0	95.9	97.8	93.6
Florida	2.3	94.7	97.0	95.8
Georgia	_	_		_
Maryland	57.1	98.2	97.9	98.6/99.2/99.1
North Carolina ^{††}	8.3	90.8	94.1	90.7
South Carolina		—	—	—
Virginia	1.8	92.0	97.0	88.0
West Virginia	81.0	96.5	96.7	96.6

TABLE 3. Estimated vaccination coverage among children enrolled in licensed child care centers, by reporting area and vaccine - 64 vaccination programs, United States and selected territories, 1999-2000 school year

* The proportion of eligible children included in the assessment survey.

¹ At least 3 doses of poliovirus vaccine unless otherwise indicated. ⁵ At least 3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), diphtheria and tetanus toxoids (DT), or tetanus toxoid (Td) unless otherwise indicated.

¹ One dose of measles vaccine, 1 dose of mumps vaccine, and 1 dose of rubella vaccine. Each antigen reported separately unless otherwise indicated.

** At least 4 doses of DTaP, DT, or Td.

⁺⁺ Measles, mumps, and rubella coverage reported for combined measles, mumps, and rubella vaccine (MMR). One dose of MMR unless otherwise indicated.

	%			
Reporting area	Population assessed*	% Poliovirus⁺	% DTaP/DT/Td⁵	% M/M/R¶
	assesseu	Pollovirus		
East South Central				
Alabama	—	—	—	—
Kentucky	45.0	93.0	93.0	94.0
Mississippi	3.5	95.8	98.4	94.9
Tennessee	—		—	—
West South Central				
Arkansas	44.0	92.0	90.0	95.0
Louisiana	100.0	91.0	96.0	83.0
Oklahoma	—		—	—
Texas	—	—	—	—
Houston	—		—	—
San Antonio	—		—	—
Mountain				
Arizona	99.6	97.5	98.6	97.7
Colorado	_	_	—	_
ldaho	_	_	—	_
Montana	_	94.0	99.0	91.0
Nevada	100.0	96.6	97.7	97.9
New Mexico	8.0	87.0	93.0	80.0
Utah	86.9	97.6	96.8	97.4/97.4/97.1
Wyoming	100.0	93.7	95.1	95.1
Pacific				
Alaska ^{tt}	61.8	93.9	88.4	96.2
California	99.2	97.4	97.8	97.7
Hawaii	99.4	99.8	99.9	99.9
Oregon	99.0	93.6	94.4	93.4
Washington	83.0	97.0	100.0	97.0
Territories				
American Samoa	_			_
Guam	_			_
Marshall Islands	_			_
Micronesia	_			_
Northern Mariana				
Islands	_	99.0	95.0	95.0
Palau	_			
Puerto Rico	52.0	90.0	89.0	96.0
Virgin Islands			_	
No. achieving <u>></u> 95%				
coverage goal		20	23	22/23/23

TABLE 3. (Continued) Estimated vaccination coverage among children enrolled in licensed child care centers, by reporting area and vaccine — 64 vaccination programs, United States and selected territories, 1999-2000 school year

* The proportion of eligible children included in the assessment survey.
 † At least 3 doses of poliovirus vaccine unless otherwise indicated.
 § At least 3 doses of diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), diphtheria and tetanus

toxoids (DT), or tetanus toxoid (Td) unless otherwise indicated. ¹ One dose of measles vaccine, 1 dose of mumps vaccine, and 1 dose of rubella vaccine. Each antigen reported separately unless otherwise indicated. ** At least 4 doses of DTaP, DT, or Td.

⁺⁺ Measles, mumps, and rubella coverage reported for combined measles, mumps, and rubella vaccine (MMR). One dose of MMR unless otherwise indicated.

Vaccination Coverage — Continued

levels might have been lower because younger children, for whom the complete basic series of vaccines was not yet applicable, were included in the survey data.

The findings in this report are subject to at least five limitations. First, approximately 30% of the participating programs did not submit 1999–2000 vaccination coverage data for the survey. Second, coverage estimates reported by programs might have varied because of differences in state vaccination requirements. Third, not all programs assessed vaccination coverage for all eligible children. Fourth, children attending private schools were not surveyed by all of the programs. Finally, because children at licensed child care centers represented a wide range of ages and some centers did not report the ages of all children participating in the survey, it was impossible to determine the reasons for lower coverage levels among these children.

The implementation and enforcement of state vaccination requirements have resulted in high levels of coverage among the U.S. school-aged and licensed child care population attending these facilities. State requirements constitute an important component of the effort to meet 2010 objectives and ensure vaccination of children aged 5 and 6 years who had not been vaccinated during early childhood (*6*,*7*).

References

- 1. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997;278:1495–9.
- 2. CDC. Transmission of measles among a highly vaccinated school population—Anchorage, Alaska, 1998. MMWR 1999;47:1109–11.
- 3. US Department of Health and Human Services. Healthy people 2010 (conference ed, 2 vols). Washington, DC: US Department of Health and Human Services, 2000.
- Jiles RB, Fuchs C, Klevens RM. Vaccination coverage among children enrolled in Head Start programs or day care facilities or entering school. In: CDC surveillance summaries (September 22). MMWR 2000;49(no. SS-9):27–38.
- Orenstein WA, Hinman AR, Williams WW. The impact of legislation on immunisation in the United States. In: Hall R, Richters J, eds. Immunisation: the old and the new. Proceedings of the 2nd National Immunisation Conference, May 27–29, 1991. Canberra, Australia: Public Health Association of Australia, 1992:58–62.
- 6. Orenstein WA, Bernier RH. Surveillance—information for action. Pediatr Clin North Am 1990;37:709–34.
- 7. Orenstein WA, Hinman AR. The immunization system in the United States—role of school immunization laws. Vaccine 1999;17:S19–S24.

Public Health Dispatch

Update: Outbreak of Poliomyelitis — Dominican Republic and Haiti, 2000–2001

From July 12, 2000, through September 18, 2001, a total of 21 cases of poliomyelitis (including two fatal cases) were reported from the Caribbean island of Hispaniola, divided between Haiti and the Dominican Republic (*1,2*). In the Dominican Republic, 13 of 168 reported cases of acute flaccid paralysis (AFP) were confirmed as polio by isolation of poliovirus type 1 from either patients or their healthy contacts. The median age of the patients was 3 years (range: 9 months–14 years). None was vaccinated adequately. The

Outbreak of Poliomyelitis — Continued

most recent confirmed case-patient in the Dominican Republic had paralysis onset on January 25, 2001. In Haiti, eight of 40 AFP cases were confirmed virologically; seven of the confirmed cases occurred during January–July 2001. The median age of the patients was 7 years (range: 2–12 years). One patient had received at least 3 doses of oral poliovirus vaccine (OPV). The most recent confirmed case occurred in Haiti and the patient had paralysis onset on July 12, 2001. Eighteen AFP cases from the Dominican Republic and three from Haiti are pending final classification.

This outbreak was the first in the Americas since 1991 and was associated with the circulation of a type 1 OPV-derived virus, having substitutions affecting 1.8% to 4.1% of nucleotides encoding the major capsid protein (VP1). The circulating vaccine-derived poliovirus associated with the outbreak recovered the capacity to cause paralytic disease and widespread person-to-person transmission and was biologically indistinguishable from type 1 wild poliovirus. Contemporary vaccine-derived poliovirus isolates from persons with AFP cases in other countries of the Americas are more closely related (>99.5% VP1 sequence similarity) to the respective OPV strains, are unrelated to the Hispaniola outbreak viruses, and show no evidence of extensive person-to-person transmission. The outbreak in Hispaniola occurred in areas of very low OPV coverage.

In response to the outbreak, health authorities in both countries conducted house-tohouse vaccination with OPV. Three rounds of mass vaccination campaigns were conducted in the Dominican Republic in December 2000, and February and April 2001. In each round, approximately 1.2 million OPV doses were administered to an estimated population of 1.1 million children aged <5 years. Haiti conducted two rounds of mass vaccination in February and March 2001. However, these campaigns were hampered by logistic difficulties and heavy rains and reached an estimated 40% of the 1.2 million children aged <5 years. During May–July 2001, a door-to-door and school-based campaign among all 2.3 million children aged <10 years was conducted sequentially in all of the country's departments. Preliminary results suggest that 2.4 million OPV doses were administered, and a second door-to-door campaign is under way.

Travelers to the Dominican Republic and Haiti who are not vaccinated adequately are at risk for polio. Travelers should have received poliovirus vaccination according to national vaccination policies (*3*).

Reported by: Ministry of Health, Pan American Health Organization, Santo Domingo, Dominican Republic. Ministry of Health, Pan American Health Organization, Port-au-Prince, Haiti. Caribbean Epidemiology Center Laboratory, Pan American Health Organization, Trinidad and Tobago. Div of Vaccines and Immunization, Pan American Health Organization, Washington, DC. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Vaccine Preventable Disease Eradication Div, National Immunization Program, CDC.

References

- 1. CDC. Outbreak of poliomyelitis—Dominican Republic and Haiti, 2000. MMWR 2000;49: 1094–103.
- 2. CDC. Outbreak of poliomyelitis—Dominican Republic and Haiti, 2000–2001. MMWR 2001;50:147–8.
- 3. CDC. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(no.RR-5).

Weekly Update: West Nile Virus Activity — United States, September 26–October 2, 2001

The following report summarizes West Nile virus (WNV) surveillance data reported to CDC through ArboNET and verified by states and other jurisdictions as of October 2, 2001.

During the week of September 26–October 2, five human cases of WNV encephalitis were reported in Connecticut (two) and New Jersey (three); no deaths were reported. During the same period, WNV infections were reported in 539 crows, 239 other birds, and 19 horses. A total of 52 WNV-positive mosquito pools were reported in four states (Connecticut, Massachusetts, New Jersey, and Ohio).

During 2001, 25 human cases of WNV encephalitis have been reported in New York (six), Connecticut (five), Maryland (five), Florida (four), New Jersey (four), and Georgia (one); one death occurred in Georgia. A total of 3,060 crows and 1,191 other birds with WNV infection were reported from 23 states and the District of Columbia (Figure 1); 108 WNV infections in other animals (all horses) were reported from 11 states (Alabama, Connecticut, Florida, Georgia, Kentucky, Louisiana, Massachusetts, Mississippi, New York, Pennsylvania, and Virginia); and 620 WNV-positive mosquito pools were reported from 12 states (Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, and Rhode Island).

Additional information about WNV activity is available at http://cindi.usgs.gov/hazard/event/west_nile/west_nile.htm




FIGURE 1. Areas reporting West Nile virus (WNV) activity — United States, 2001*

⁺ Kentucky and Mississippi reported WNV infection in a horse but no birds.

^{*} As of October 2, 2001.

858




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending September 29, 2001, with historical data

- * No rubella cases were reported for the current 4-week period yielding a ratio for week 39 of zero (0).
- [†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

	Cum. 2001		Cum. 2001
Anthrax	-	Poliomyelitis, paralytic	-
Brucellosis [†]	59	Psittacosis [†]	11
Cholera	3	Qfever [†]	18
Cyclosporiasis [†]	114	Rabies, human	1
Diphtheria	2	Rocky Mountain spotted fever (RMSF)	398
Ehrlichiosis: human granulocytic (HGE) [†]	152	Rubella, congenital syndrome	-
human monocytic (HME) [†]	63	Streptococcal disease, invasive, group A	2,748
Encephalitis: California serogroup viral [†]	50	Streptococcal toxic-shock syndrome [†]	45
eastern equine [†]	5	Syphilis, congenital [¶]	166
St. Louis ⁺	1	Tetanus	22
western equine ⁺	-	Toxic-shock syndrome	88
Hansen disease (leprosy) [†]	56	Trichinosis	17
Hantavirus pulmonary syndrome [†]	5	Tularemia [†]	81
Hemolytic uremic syndrome, postdiarrheal [†]	103	Typhoid fever	194
HIV infection, pediatric ¹⁸	153	Yellow fever	-
Plague	2		

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending September 29, 2001 (39th Week)*

-: No reported cases. *Incidence data for reporting year 2001 are provisional and cumulative (year-to-date).

⁵ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV,

STD, and TB Prevention (NCHSTP). Last update September 25, 2001. ¹Updated from reports to the Division of STD Prevention, NCHSTP.

	AIDS		Chlan	nydia⁵	Cruptos	poridiosis	NE		coli O157:H	7 [†] LIS
	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2001 [¶] 29,580	2000 29,952	2001 513,425	2000 518,744	2001 2,097	2,189	2001 2,065	2000 3,528	2001 1,619	2000 2,945
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	1,129 36 31 13 602 78 369	1,586 27 27 29 998 75 430	17,036 802 979 448 7,068 2,206 5,533	17,379 1,085 823 394 7,344 1,970 5,763	100 14 10 30 38 3 5	109 17 17 23 31 3 18	197 24 29 13 99 10 22	311 24 29 30 142 14 72	172 26 23 8 77 9 29	328 25 31 33 147 16 76
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	6,710 731 3,385 1,389 1,205	6,678 662 3,609 1,295 1,112	56,845 10,144 21,719 8,393 16,589	48,209 1,403 19,724 8,210 18,872	199 81 68 7 43	285 79 142 14 50	161 122 8 31 N	350 222 21 107 N	163 121 8 34	250 48 15 107 80
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	2,238 430 264 992 413 139	2,865 430 282 1,568 437 148	77,657 15,766 10,690 20,387 22,321 8,493	89,243 23,456 9,858 25,038 18,714 12,177	767 143 62 1 137 424	745 190 49 94 78 334	527 131 62 118 72 144	869 207 99 166 113 284	391 124 38 107 62 60	625 188 74 132 95 136
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	637 108 71 312 2 22 52 70	680 129 69 318 2 7 53 102	25,241 4,958 1,858 9,969 699 1,345 2,148 4,264	29,156 6,032 3,982 9,776 672 1,364 2,802 4,528	317 120 70 33 9 6 78 1	214 22 63 26 9 13 72 9	315 95 72 40 12 33 49 14	492 112 149 91 15 46 56 23	283 98 48 62 26 40 - 9	496 159 128 82 17 52 44 14
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	9,497 203 1,506 644 723 61 726 577 1,031 4,026	8,257 156 1,056 569 556 46 505 639 991 3,739	97,702 2,041 8,381 2,221 13,852 1,752 15,420 8,600 19,519 25,916	98,052 2,153 10,538 2,400 11,870 1,587 16,860 7,146 20,700 24,798	245 5 32 10 18 2 23 - 86 69	341 5 9 12 15 3 21 - 120 156	177 4 23 - 46 9 36 7 20 32	293 2 27 1 55 13 70 19 35 71	120 6 1 U 36 8 28 11 15 15	243 1 U 51 10 62 16 36 66
E.S. CENTRAL Ky. Tenn. Ala. Miss.	1,423 278 456 347 342	1,507 159 635 395 318	35,943 6,751 11,057 9,640 8,495	38,073 5,966 10,827 11,969 9,311	38 4 12 12 10	39 5 10 12 12	98 44 32 15 7	106 32 47 7 20	88 39 36 6 7	87 27 43 7 10
W.S. CENTRAL Ark. La. Okla. Tex.	3,141 159 665 186 2,131	3,005 149 493 259 2,104	77,144 5,426 12,829 7,906 50,983	78,447 5,002 13,793 6,594 53,058	26 6 7 11 2	133 10 10 13 100	51 8 3 23 17	204 54 13 14 123	64 - 25 24 15	253 37 42 14 160
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	1,073 14 17 3 231 103 437 90 178	1,105 11 19 7 259 116 348 108 237	29,994 1,465 1,378 605 6,482 4,193 10,683 1,494 3,694	29,330 1,023 1,381 598 8,385 3,650 9,757 1,606 2,930	163 25 19 4 32 20 6 53 4	128 10 12 5 57 13 10 17 4	222 16 49 5 77 11 22 28 14	344 29 58 14 125 19 42 46 11	86 - 1 30 9 21 24 1	250 32 9 89 16 32 62 10
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	3,732 395 154 3,112 16 55	4,269 379 113 3,669 15 93	95,863 10,196 5,473 75,337 1,974 2,883	90,855 9,732 5,185 71,400 1,869 2,669	242 43 36 159 1 3	195 U 14 181 -	317 87 50 159 4 17	559 175 114 231 26 13	252 62 37 147 6	413 181 103 116 3 10
Guam P.R. V.I. Amer. Samoa C.N.M.I.	10 934 2 -	13 1,023 27 -	1,930 53 U 96	366 U - U U	- - - U -	- - - U U	N 1 - U	N 6 - U U		

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending September 29, 2001, and September 30, 2000 (39th Week)*

: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands. Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date). N: Not notifiable.

Cumulative (year-to-cate). Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS). Chlamydia refers to genital infections caused by *C. trachomatis.* Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update September 25, 2001. t

§

1

		rrhea	Hepati Non-A,	tis C;	Legione		Listeriosis	Ly	rme ease
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	235,999	264,359	2,443	2,384	720	786	338	9,114	12,860
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	4,838 88 138 51 2,174 606 1,781	4,918 69 84 48 2,008 474 2,235	14 - 6 8 -	23 2 4 12 5	46 6 5 12 6 9	44 2 4 16 5 15	38 - 4 2 18 1 1 3	2,983 - 104 12 558 393 1,916	4,045 51 28 1,043 315 2,608
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	28,442 6,113 9,152 5,127 8,050	28,529 5,347 8,542 5,472 9,168	1,197 45 - 1,107 45	535 28 - 471 36	141 46 13 7 75	214 59 31 18 106	53 22 8 10 13	4,537 2,497 2 783 1,255	6,727 2,789 156 2,249 1,533
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	41,999 8,782 4,574 12,712 12,981 2,950	53,222 14,253 4,628 15,752 13,356 5,233	133 8 1 12 112	182 9 - 18 155 -	187 94 15 - 53 25	211 87 30 26 35 33	42 13 4 19 5	451 102 17 1 331	706 49 21 33 21 582
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak.	10,910 1,596 428 6,091 27 220	12,900 2,381 892 6,222 56 225	527 8 508 -	434 5 1 417 -	44 9 7 18 1 3	47 3 13 22 - 2	11 - 1 6 -	298 245 27 21	242 156 24 44 1
Nebr. Kans.	705 1,843	1,113 2,011	3 8	4 7	5 1	3 4	1 3	3 2	3 14
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	60,465 1,212 4,643 2,025 8,088 497 12,681 5,836 10,676 14,807	69,206 1,269 7,211 1,871 7,755 492 13,788 6,370 13,243 17,207	84 - - 9 16 6 - 40	72 2 10 3 14 13 2 3 22	155 6 30 7 19 N 7 10 9 67	144 8 3 27 N 13 4 6 35	55 - 10 - 9 5 2 4 11 11 14	681 49 430 8 103 10 33 5 - 43	928 167 543 4 123 26 41 5 - 19
E.S. CENTRAL Ky. Tenn. Ala. Miss.	23,194 2,646 7,455 7,519 5,574	27,402 2,634 8,693 9,213 6,862	163 8 52 3 100	362 30 75 7 250	44 9 21 12 2	26 15 8 2 1	16 4 7 5	43 19 15 8 1	42 8 26 5 3
W.S. CENTRAL Ark. La. Okla. Tex.	37,766 3,287 8,845 3,598 22,036	41,364 2,948 10,183 2,894 25,339	165 3 78 3 81	575 7 326 7 235	5 - 2 3 -	21 - 7 2 12	6 1 - 2 3	7 - 1 - 6	69 5 7 57
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	7,523 83 60 59 2,213 679 2,929 117 1,383	7,928 31 64 39 2,419 810 3,287 164 1,114	55 1 2 6 17 11 9 3 6	60 4 3 12 13 14 - 12	41 2 1 12 2 16 5 3	29 1 4 10 1 7 6	29 - 1 7 6 6 2 6	11 - 6 1 1 - - 1 2	9 - 2 3 - - 1 3
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	20,862 2,259 852 16,991 310 450	18,890 1,704 711 15,864 259 352	105 17 12 76 -	141 24 23 92 - 2	57 7 N 46 - 4	50 14 N 35 - 1	88 7 6 69 - 6	103 8 6 87 2 N	92 7 8 75 2 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	461 6 U 9	43 395 - U U	- 1 - U -	3 1 - U U	2 - - -	- 1 - U U	- - - -	N - U	N U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending September 29, 2001, and September 30, 2000 (39th Week)*

N: Not notifiable. U: Unavailable. - : No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

						Salmonellosis [†]			
	Ma	laria	Rabies	s, Animal	NE	TSS		HLIS	
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	
UNITED STATES	872	1,094	4,832	5,418	25,755	29,106	21,440	24,964	
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	61 4 2 1 25 7 22	59 5 1 2 29 6 16	564 52 20 51 203 48 190	622 103 9 48 214 45 203	1,892 148 144 61 1,062 110 367	1,737 101 103 96 1,017 106 314	1,656 137 129 63 801 139 387	1,790 78 113 94 1,022 125 358	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	215 53 105 25 32	285 50 165 40 30	954 611 22 155 166	986 618 9 148 211	3,178 918 750 651 859	3,820 911 965 937 1,007	2,951 1,043 830 657 421	4,147 1,033 1,048 810 1,256	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	81 21 15 1 30 14	115 15 57 26 12	115 42 3 23 41 6	138 46 - 20 61 11	3,631 1,065 404 915 623 624	4,086 1,065 494 1,242 686 599	3,363 1,036 377 943 617 390	2,720 1,141 495 15 753 316	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	29 6 5 11 - 2 5	44 13 2 13 2 - 8 6	277 39 66 36 33 25 4 74	451 71 66 43 103 81 1 86	1,608 399 264 463 43 118 122 199	1,863 428 283 547 48 78 181 298	1,745 474 222 705 69 111 - 164	2,024 552 275 666 64 89 125 253	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	233 2 100 13 43 1 12 6 12 44	247 4 82 15 44 3 27 2 16 54	1,755 30 257 349 115 459 92 294 159	1,852 41 332 443 91 448 123 251 123	6,550 77 651 65 1,082 96 980 641 1,015 1,943	5,866 94 615 50 772 128 829 560 1,019 1,799	4,489 87 678 U 747 107 905 532 1,061 372	4,578 104 550 U 727 118 868 436 1,355 420	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	30 12 11 5 2	38 14 10 13 1	169 21 91 55 2	163 18 85 59 1	1,891 281 470 546 594	1,738 300 438 480 520	1,355 143 586 409 217	1,390 210 624 456 100	
W.S. CENTRAL Ark. La. Okla. Tex.	10 3 4 2 1	64 3 10 7 44	516 20 54 442	722 20 3 50 649	1,797 625 286 340 546	3,683 528 619 305 2,231	1,461 92 566 292 511	2,248 445 510 237 1,056	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	42 2 3 - 19 3 6 3 6	38 1 3 - 20 - 6 4 4	204 31 24 20 - 13 104 11 1	228 57 9 49 - 18 77 10 8	1,650 60 111 50 452 220 463 176 118	2,139 71 98 52 578 187 553 381 219	1,306 4 43 458 170 472 136 23	1,993 92 44 553 172 575 379 178	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	171 6 10 145 1 9	204 23 32 139 10	278 2 239 37	256 7 224 25	3,558 401 184 2,652 32 289	4,174 417 238 3,290 47 182	3,114 491 244 2,094 2 283	4,074 528 293 3,035 32 186	
Guam P.R. V.I. Amer. Samoa	- 3 - U	2 4 - U	73 Ū	60 - U	455 - U	21 499 - U	U U U U	U U U U	
C.N.M.I.	-	Vailable	- - No repo	U	10	Ŭ	Ŭ	Ŭ	

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,weeks ending September 29, 2001, and September 30, 2000 (39th Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

¹ Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

Weeks	chung o	Shige				philis			
	NET			HLIS	(Primary 8	Secondary)		rculosis	
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	
UNITED STATES	12,265	16,676	5,850	9,514	4,266	4,553	8,928	10,558	
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	214 6 7 157 17 21	317 10 4 229 22 48	184 2 3 5 116 20 38	309 11 8 - 211 25 54	43 - 1 2 24 8 8	61 1 43 4 12	320 8 11 4 182 28 87	310 12 16 4 183 27 68	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	1,019 405 265 185 164	2,080 589 828 443 220	618 101 268 184 65	1,344 179 575 378 212	364 21 200 86 57	216 9 91 53 63	1,731 251 889 371 220	1,685 223 909 398 155	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	3,215 2,273 166 311 244 221	3,396 286 1,292 977 570 271	1,497 1,024 30 248 171 24	937 234 137 5 517 44	732 64 125 218 307 18	918 62 277 320 217 42	956 166 77 459 197 57	1,017 214 100 475 159 69	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	1,279 296 331 251 20 263 59 59	1,838 603 400 554 14 6 96 165	1,024 341 265 156 24 206 32	1,551 680 275 384 39 4 74 95	60 22 1 16 - 4 17	56 13 10 26 - - 2 5	340 167 34 97 3 10 29	380 118 27 146 2 14 17 56	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,840 12 121 45 245 8 283 219 188 719	2,125 18 154 63 343 4 162 106 191 1,084	604 10 67 U 124 8 143 107 111 34	916 19 87 U 275 3 220 76 146 90	1,508 9 177 37 84 - 344 189 276 392	1,516 8 229 30 105 3 387 160 292 302	1,725 15 160 51 24 252 134 323 575	2,192 14 192 22 198 22 271 206 477 790	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	1,062 388 77 182 415	789 309 269 52 159	407 175 79 124 29	421 58 316 41 6	466 35 249 91 91	676 63 404 98 111	568 83 207 200 78	706 86 266 239 115	
W.S. CENTRAL Ark. La. Okla. Tex.	1,107 439 117 48 503	2,607 160 215 87 2,145	721 155 137 17 412	812 44 138 33 597	534 27 119 52 336	621 77 171 93 280	727 115 - 100 512	1,530 148 135 118 1,129	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	722 4 31 3 177 101 296 47 63	881 7 43 5 193 109 352 66 106	500 - 1 183 66 201 41 8	621 25 3 148 73 235 71 66	183 - 1 33 16 117 8 7	180 - 1 8 14 151 1 4	359 6 8 3 81 21 159 29 52	388 10 7 63 34 157 37 78	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,807 152 63 1,532 5 55	2,643 363 145 2,098 7 30	295 167 78 - 1 49	2,603 342 94 2,138 3 26	376 37 13 316 10	309 51 10 247 1	2,202 184 81 1,790 39 108	2,350 188 73 1,906 83 100	
Guam P.R. V.I. Amer. Samoa	- 8 - U	34 28 U	U U U U	U U U U	172 U	3 127 Ū	- 76 - U	41 119 - U	
C.N.M.I.	4	U	U	U	3	Ŭ	22	Ŭ	

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States	3,
weeks ending September 29, 2001, and September 30, 2000 (39th Week)*	

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date). † Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

Reporting Area Reporti		H. influenzae, Hepatitis (Viral), By Type Measles (Rubeola)											
Reperfundances 2000 2001 2000 2001 2000 2001 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 2000 71 NEW ENGLAND 65 75 439 278 4.87 5.18 - 4 - 1 5 6 -					cputitis (v		pe						
UNITED STATES 992 949 7,142 9,767 4,873 5,218 - 48 - 42 90 71 Maine GLAND 66 75 4303 259 76 85 - 4 - 1 - 7 - 3 Maine 3 7 10 8 4 6 - 1 - 7 - 3 Mass. 3 7 10 18 44 6 - 1 - 7 - 1 3 Mass. 3 7 10 18 44 6 - 1 - 7 - 1 3 Mass. 3 7 10 18 44 6 - 1 - 7 - 1 3 Conn, 19 15 194 121 73 13 5 - 1 - 7 - 1 3 Conn, 19 15 194 121 73 13 5 - 1 - 7 - 1 3 Conn, 19 15 194 121 73 13 5 - 1 - 7 - 1 3 Conn, 19 15 194 121 73 13 5 - 1 - 7 - 1 3 Conn, 19 15 194 121 73 13 5 - 1 - 7 - 1 3 MID.ATLANT(C 148 77 115 122 115 - 2 - 1 1 3 10 N.Y.City 38 42 20 340 220 340 - 2 - 1 3 10 N.Y.City 38 32 129 319 219 188 140 - 7 - 1 1 1 - 7 Fa. CUTRAL 132 144 775 1273 675 547 3 3 4 2 Upstate 1 - 7 4 87 88 80 3 3 4 2 Unit. 10 46 121 571 1273 675 547 3 3 4 2 Unit. 10 46 121 571 1273 675 547 3 3 4 2 Unit. 10 46 121 553 118 90 3 3 4 2 UNI.CUTRAL 132 144 775 1273 675 547 3 3 4 2 UNI.CUTRAL 132 144 775 1273 675 847 3 3 4 2 UNI.CUTRAL 132 144 775 1273 675 847 3 3 4 2 UNI.CUTRAL 132 144 775 1273 675 847 3 3 4 2 UNI.CUTRAL 132 144 775 1273 675 847 3 3 4 2 UNI.CUTRAL 132 144 775 1273 675 847 3 3 4 UNI.CUTRAL 133 148 88 10 3 3 4 UNI.CUTRAL 133 148 79 0 3 3 4 UNI.CUTRAL 131 79 322 12 71 115 22 224 - 4 4 4 1 MID.ATLANT(C 2 - 0 - 2 2 MIL 1 1 4 133 88 15 21 N.Dak. 6 2 2 3 11 1 1 7 2 N.Dak. 6 12 2 3 11 1 1 2	Reporting Area							2001		2001			
Maine 1 1 100 15 5 5 - 1 3 3 2 1 - 1 1 0<													
N.H. 4 12 12 18 12 15 - - - - 3 Mas. 3 36 173 115 2 15 - - - 1 3 Mas. 36 36 172 115 2 - - - - - - MD.ATLANTIC 148 179 720 117 799 890 - 4 - - 1 5 21 Upstate NY, 58 75 188 172 104 930 - - - 1 1 - 1 5 10 N.J. 38 32 159 188 140 - - - 10 0 7 Pat. 16 23 164 946 205 219 - - - 3 3 2 Unit. 40 46 218 553 113 90 - - - 3 3 2 Win. 7 9 254 362 434 297 - - - - -2 Win. 7													
Mass. 36 36 175 115 2 13 - 2 - 1 - - - - - - - - - - - - - - - 1 - - 1 - - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 <th1< th=""> 1 1 <th< td=""><td>N.H.</td><td>4</td><td>12</td><td>12</td><td>18</td><td>12</td><td>15</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>3</td></th<></th1<>	N.H.	4	12	12	18	12	15	-	-	-	-	-	3
Conn. 19 15 194 121 31 35 - 1 - 1 - 1 - 1 - 1 - 1 15 21 Upstate N.Y. 88 75 188 1172 194 98 - 1 - 1 1 1 5 10 N.Y. City 38 32 159 219 168 140 - - - 1 1 1 - 5 6 1 1 - 5 6 1 1 - 5 6 1 1 - 1 <td></td> <td>3 35</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td></td> <td></td> <td>3</td>		3 35						-		-			3
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								-		-			-
N.Y.City. 36 49 209 380 322 438 - 2 - 1 3 10 Pa. 16 23 164 346 205 219 - 1 - 5 6 1 Pa. 16 23 164 181 215 86 88 - - - 3 3 2 Ch.NCENTRAL 132 147 775 1273 675 547 - - - 3 3 2 Ind. 10 48 215 365 118 90 - - - - 3	MID. ATLANTIC							-		-	11	15	
N.J. 38 32 159 219 168 140 - - 1 - 5 6 1 E.N.CENTRAL 132 147 775 1.273 675 547 - - - 3 3 2 Ind. 40 26 75 74 37 40 - - - 4 4 - Mich. 7 9 254 362 434 297 - - - - 2 1 - - 2 1 - - - 2 1 1 0 - - - - 2 1 1 0 - - 2 1 1 0 - - 2 1 1 0 - - 2 1 1 0 0 1 1 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1								-					
E.N. CENTRAL 132 147 775 1273 675 547 10 10 7 Dhio 53 44 175 275 1273 675 547 3 3 3 Mich. 7 9 254 362 434 297 3 2 Wis. 22 9 47 69 - 32 3 2 Wis. 22 7 9 247 69 - 32 2 1 Minn. 30 29 33 161 17 30 - 2 2 1 Nowa 29 59 19 27 2 N. Dak. 6 2 2 3 3 161 77 30 - 2 2 1 Nok. 6 2 2 3 3 161 77 30 - 2 2 - 1 N. Dak. 6 2 1 2 3 17.78 112 224 - 4 1 N. Dak. 6 2 1 2 3 17 12 N. Dak. 6 2 1 2 3 16 17 32	N.J.	38	32	159	219	168	140	-	-		1	1	-
								_	-				
III. 10 48 218 553 118 90 - - - 3 3 Wis. 22 20 47 69 - 32 - <td>Ohio</td> <td>53</td> <td>44</td> <td>181</td> <td>215</td> <td>86</td> <td>88</td> <td>-</td> <td>-</td> <td></td> <td>3</td> <td>3</td> <td>2</td>	Ohio	53	44	181	215	86	88	-	-		3	3	2
Wis. 22 20 47 60 - 32 -	III.	10	48	218	553	118	90	-	-		3	3	3
Minn. 30 29 33 161 17 30 - 2 - - 2 1 Mo. 13 18 88 233 83 111 - </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td> <td>-</td> <td>-</td>								-	-	-		-	-
iowa - - 29 59 19 27 - DLC V								-		-	-		
N.Dak. 6 2 2 3 - 2 - </td <td>lowa</td> <td>-</td> <td>-</td> <td>29</td> <td>59</td> <td>19</td> <td>27</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td> <td>-</td>	lowa	-	-	29	59	19	27	-	-	-	-	-	-
Nebr. 1 3 29 26 17 32 -	N. Dak.		2	2	3	-	2	-		-	-		-
S. ATLANTIC 291 213 1,778 1,054 1,041 908 - 4 - 1 5 3 Del. - - - 12 - 12 -								-		-	-	-	-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								-	-	-	-	-	-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Del.	-	-	-	12	-	12	-	-	-	-	-	3
Va. 21 33 104 118 126 124 - 1 - - 1 2 N.C. 41 20 157 116 161 182 - 1 - - 1 - - 1 - - 1 - - - - - - 1 - - 1 - - 1 - - - - - - - - - - - - - <t< td=""><td></td><td></td><td>63</td><td></td><td></td><td></td><td></td><td>-</td><td></td><td>-</td><td></td><td></td><td>-</td></t<>			63					-		-			-
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$								-		-	-	1	2
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	N.C.	41	20	157	116	161	182	-	-	-	-	-	-
ES. CENTRAL 62 303 330 338 357 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 1 7 1	Ga.	68	54	672	198	244	155	-	-	-	-		-
Ky,212107424062-22-Tenn.3216112115178178167Miss.22161305484 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td>-</td><td>-</td><td></td><td>-</td></t<>								-		-	-		-
Ala. 26 9 68 43 66 44 -	Ky.	2	12	107	42	40	62	-	2	-	-	2	-
W.S. CENTRAL 36 59 647 1.869 491 843 - 1 - - 1 - Ark. - 2 59 118 75 78 - 1 0 5 3 6 - - - 1 1 0 1 3 51 21 10 6 - - - - - - - - - - - - 1 1 1 1 1	Ala.	26	9	68	43	66	44	-	-	-	-	-	-
Ark. - 2 59 118 75 78 -								-	-	-	-	-	-
Okla. 33 39 100 205 70 117 - 1 - - 1 - - 1 - - 1 - - 1 - - 1 - - 1 - - 1 - - 1 - - 1 - - 1 1 0 5 3 6 - - - 1 1 -	Ark.	-	2	59	118	75	78	-	-	-	-	-	-
MOUNTAIN 118 91 602 697 404 395 - 1 - 1 2 12 Mont. - 1 10 5 3 6 - 1 - - - - - - - - -	Okla.		39	100	205	70	117	-		-	-	-	-
Mont. - 1 10 5 3 6 - <td></td> <td>- 118</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td></td> <td>- 12</td>		- 118						-		-	-		- 12
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mont.	-	1	10	5	3	6	-	-		-	-	-
N. Mex.181930601221111-10111111111111111111111111111111111111 <th1< th="">1111<th1< th=""><</th1<></th1<>	Wyo.	-	1	7	4	2	2	-	-	-	-	-	-
Nev. 10 3 49 51 36 38 - - - - 7 PACIFIC 89 89 1,556 2,578 897 965 - 28 - 18 46 21 Wash. 2 5 105 219 109 77 - 13 - 2 15 3 Oreg. 17 26 64 146 75 84 - 3 - - 3 - Calif. 42 30 1,372 2,189 689 784 - 10 - 11 21 14 Alaska 6 6 14 11 9 9 - - - 1 1 Hawaii 22 22 1 13 15 11 - 2 - 5 7 3 Guam - 1 - 1 - 9 - - - - 2 - 5 7 3 <td>N. Mex.</td> <td>18</td> <td>19</td> <td>30</td> <td>60</td> <td>122</td> <td>111</td> <td>-</td> <td></td> <td>-</td> <td>-</td> <td>-</td> <td></td>	N. Mex.	18	19	30	60	122	111	-		-	-	-	
PACIFIC 89 89 1,556 2,578 897 965 - 28 - 18 46 21 Wash. 2 5 105 219 109 77 - 13 - 2 15 3 Oreg. 17 26 64 146 75 84 - 3 - - 3 - Calif. 42 30 1,372 2,189 689 784 - 10 - 11 21 14 Alaska 6 6 14 11 9 9 - - - 1 1 Hawaii 22 22 1 13 15 11 - 2 - 5 7 3 Guam - 1 - 1 - 9 - - - - 2 - 5 7 3 Guam - 1 3 91 210 136 211 - - - -		52 6	35 7			123 22		-	1 -	-	-	1	- 3
Oreg. 17 26 64 146 75 84 - 3 - - 3 - Calif. 42 30 1,372 2,189 689 784 - 10 - 11 21 14 Alaska 6 6 14 11 9 9 - - - 1 1 Hawaii 22 22 1 13 15 11 - 2 - 5 7 3 Guam - 1 - 1 - 9 - 1 - 1 - 1								-	-	-	-	-	
Oreg. 17 26 64 146 75 84 - 3 - - 3 - Calif. 42 30 1,372 2,189 689 784 - 10 - 11 21 14 Alaska 6 6 14 11 9 9 - - - 1 1 Hawaii 22 22 1 13 15 11 - 2 - 5 7 3 Guam - 1 - 1 - 9 - 1 - 1 - 1	Wash.	89 2	5	105	219		77	-	13	-		15	21 3
Hawaii 22 22 1 13 15 11 - 2 - 5 7 3 Guam - 1 - 1 - 9 - - - - - - P.R. 1 3 91 210 136 211 - - - - 2 V.I. - - - - - - - 2 Amer. Samoa U U U U U U U U	Oreg. Calif.	17	26		146 2,189	75 689		-		-			-
Guam - 1 - 9 - - - - - - - - - - - - - - - 2 2 2 1 3 91 210 136 211 - - - 2 2 2 1 1 3 91 210 136 211 - - 2 2 1 1 1 1 1 1 2 1	Alaska	6 22	6	14	11	9	9		-	-	-	-	1
V.I U - U	Guam	-	1	-	1	-	9	-	-	-	-	-	-
Amer. Samoa U U U U U U U U U U U U	V.I.	-	-	-	-	-	-	U	-	U	-	-	-
	Amer. Samoa C.N.M.I.						U U						

 TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 29, 2001, and September 30, 2000 (39th Week)*

N: Not notifiable.
U: Unavailable.
-: No reported cases.
* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).
* For imported measles, cases include only those resulting from importation from other countries.
* Of 212 cases among children aged <5 years, serotype was reported for 108, and of those, 19 were type b.

	Meningococcal Disease			Mumps			Pertussis	,	Rubella			
Reporting Area	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	
UNITED STATES	1,663	1,690	3	166	266	72	3,422	4,982	-	19	124	
NEW ENGLAND Maine N.H. Vt. Mass.	91 3 12 5 49	101 8 11 3 56	- - -		4 - - 1	1 - - 1	311 5 26 26 232	1,232 35 86 186 871			12 - 2 - 8	
R.I. Conn.	3 19	8 15	-	-	1 2	-	5 17	14 40	-	-	1 1	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	168 46 31 40 51	187 52 36 36 63	- - - -	18 3 9 2 4	21 8 6 3 4	1 1 - -	232 119 34 13 66	495 231 68 30 166		5 1 3 1	9 1 8 -	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	221 75 33 22 50 41	298 72 32 71 88 35	- - - -	15 1 1 11 2 -	19 7 1 6 4 1	11 8 2 1 -	481 253 63 58 51 56	579 263 78 76 61 101		3 - 1 2 -	1 - 1 - -	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	116 16 21 43 5 5 12	119 17 26 56 2 5 6		7 3 - - - 1	17 7 4 1 - 2		189 70 19 75 - 3 4	407 241 45 58 6 4 21		3 - 1 - - -	1 - - - 1	
Kans.	14	7	-	3	3	-	18	32	-	1	-	
S. ATLANTIC Del. Md. D.C.	319 4 37	234 	2 - -	30 - 5 -	38 - 9 -	6 - -	187 - 29 1	364 8 92 3		5 1 -	72 - -	
Va. W. Va. N.C. S.C. Ga. Fla.	33 12 59 31 38 105	36 12 32 19 39 70	- - 1 - -	6 - 4 3 7 5	8 - 10 2 4	- 5 - 1	35 2 56 31 7 26	71 1 77 24 34 54		- - 2 - 2	- 64 6 - 2	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	113 19 51 30 13	118 25 48 32 13	- - - -	6 1 - 4	5 1 2 2	16 3 11 2	109 22 52 31 4	95 46 29 17 3			6 1 1 4	
W.S. CENTRAL Ark. La. Okla. Tex.	178 17 56 25 80	178 11 40 24 103	- - - -	11 1 2 - 8	28 1 5 22	3 - - 3	307 12 2 6 287	296 33 18 16 229	- - -	1 - - 1	8 1 - 6	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz.	82 4 7 5 29 12 12	75 4 7 25 7 22	1 - - - -	11 1 1 1 2 1	17 1 - 1 - 1 4	14 - - 2 6 -	1,104 31 167 1 219 118 491	605 35 54 4 343 80 62		1 - - 1 -	2 - - 1 - 1	
Utah Nev.	7	7	- 1	1 3	4 6	6	65 12	16 11	-	-	-	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	375 56 32 274 2 11	380 40 52 272 8 8	- N - -	68 1 N 30 1 36	117 9 N 80 8 20	20 17 - - 2	502 127 43 298 3 31	909 289 96 471 18 35	- - - -	1 - - - 1	13 7 6 -	
Guam P.R. V.I.	- 4 -	9	- - U	-	12 - -	- - U	2	3 6 -	- - U	-	1 - -	
Amer. Samoa C.N.M.I.	U -	U U	Ŭ U	U	U U	Ŭ U	U -	U U	Ŭ U	U -	U U	

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 29, 2001, and September 30, 2000 (39th Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

	All Causes, By Age (Years)								All Causes, By Age (Years)						P&I⁺
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&l⁺ Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conr Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. New Bedford, Mass. New Bedford, Mass. New Haven, Coni Providence, R.I. Somerville, Mass Waterbury, Conn Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§ Jersey City, N.J. New York City, N. Newark, N.J. Paterson, N.J.	s. 19 18 27 28 6 6 6 6 8 18 1. 38 18 1. 38 16 17 1. 38 17 1. 38 18 1. 38 18 1. 38 18 1. 38 18 1. 38 18 1. 38 18 1. 38 18 1. 38 19 19 10 10 10 10 10 10 10 10 10 10	17 11 49 775 25 13 59 10 17 48 15 U U 8	30 9 4 3 7 5 1 5 13 12 1 0 3 7 197 8 2 15 6 4 11 3 UU 5	31 13 - 1 - 2 1 - 5 5 - 1 2 1 88 5 - 2 2 3 2 4 U U 3 1	12 5 - - - - - - - - - - - - - - - - - -	7 1 - - 1 - 1 - - - 1 - - - - 1 - - - -	51 20 32 32 32 2 2 31 12 66 51 92 2 1 - UU	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, I Tampa, Fla. Washington, D.U. Wilmington, De E.S. CENTRAL Birmingham, Al Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn Mobile, Ala. Montgomery, A Nashville, Tenn. W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi,	133 50 66 44 Fla. 53 206 C. 106 I. 23 907 a. 189 900 75 76 . 217 100 Ia. 40 138 1,440 86 66	$\begin{array}{c} 807\\ 807\\ 61\\ 109\\ 81\\ 86\\ 93\\ 34\\ 41\\ 35\\ 42\\ 139\\ 63\\ 23\\ 602\\ 125\\ 49\\ 48\\ 46\\ 142\\ 68\\ 31\\ 31\\ 93\\ 939\\ 52\\ 43\\ 27\\ 27\\ 27\\ 27\\ 27\\ 27\\ 27\\ 27\\ 27\\ 27$	278 30 593 32 22 211 17 7 4 43 30 - 210 44 18 20 210 44 18 20 22 47 28 305 21 21 21 21 21 21 21 21 21 21 21 21 21	110 113 215 12 11 4 2 5 16 9 - 5 9 4 3 5 5 5 15 6 2 9 127 9 9 2	29 6 2 1 7 1 1 4 - 2 3 2 - 2 6 4 2 1 3 9 - 7 3 9 - 7 3 9 - 7 3 9 - 2 - 3 9 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	37 3 7 4 6 6 6 4 - - 5 2 2 - 1 1 2 2 - 1 2 2 - 1 2 2 - 1 2 2 - 1 2 2 - - 1 2 - - - -	79 2 3 3 4 9 2 - 67 3 5 7 5 16 1 5 7 4 2 - 4
Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y. E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, III. Cincinnati, Ohio	36 65 U 40 U 1,640 43 44 U 108	311 21 13 112 16 29 51 U 27 U 1,160 26 31 U 75	5 6 16 3 6 11 8 U 310 10 2 U 12 U 14	31 1 - 8 - 1 2 U 4 U 95 5 1 U 4 - 0 4 - 0 4 - 0 5	10 1 - - - - - - - - - - - - - - - - - -	3 - - - - - - - - - - - - - - - - - - -	19 2 12 1 2 7 U 2 U 2 U 106 0 7	Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La San Antonio, Te Shreveport, La. Tulsa, Okla. MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo.	180 U 129 412 73 V x. 241 93 117 976 I.M. 127 40 5010. 57 97	109 U 84 250 43 U 183 67 81 649 72 36 63	42 U 26 92 20 U 40 18 22 191 36 3 11 15	23 U 9 52 4 U 8 2 9 81 11 2 5 13	3 U 4 15 5 U 4 2 4 33 8 2 3 2 3 2 3	3 U 6 3 1 U 5 4 1 22 1 2 4	8 U 6 24 1 U 17 3 9 67 7 1 1 5
Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind. Gary, Ind. Grand Rapids, M Indianapolis, Ind Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Oh W.N. CENTRAL Des Moines, Iow Duluth, Minn. Kansas City, Kans Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Min Omaha, Nebr. St. Paul, Minn. Wichita, Kans.	142 196 105 174 35 71 9 ich. 57 . 196 56 51 58 81 58 81 68 81 68 81 934 a 102 83 73 57 75	92 136 802 102 245 66 46 137 39 45 80 80 823 445 80 823 445 45 80 823 445 45 80 80 823 445 45 80 80 823 445 80 80 823 80 80 823 80 80 80 80 80 80 80 80 80 80 80 80 80	$\begin{array}{c} 31\\ 411\\ 17\\ 6\\ 9\\ 2\\ 7\\ 34\\ 7\\ 23\\ 5\\ 10\\ 22\\ 7\\ 148\\ 12\\ 1\\ 13\\ 12\\ 4\\ 24\\ 12\\ 213\\ 13\\ 24\\ 213\\ 13\\ 24\\ 213\\ 13\\ 24\\ 213\\ 13\\ 24\\ 213\\ 13\\ 24\\ 213\\ 13\\ 24\\ 213\\ 13\\ 24\\ 213\\ 13\\ 21\\ 21\\ 21\\ 21\\ 21\\ 21\\ 21\\ 21\\ 21\\ 21$	13 10 3 20 5 3 - 2 12 1 5 5 1 1 3 1 60 4 1 10 5 5 7 3 9 2 14	2524 - 1 - 25 - 1111 - 3 - <u>28</u> 2156 - 23513	4 4 3 1 - 2 1 - 8 - 3 - 1 - 2 2 18 1 2 1 3 - 2 2 1 1 5	6 10 11 3 7 3 3 14 5 8 4 2 2 3 2 50 4 - 5 1 3 14 8 3 2 10	Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, U Tucson, Ariz. PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Ca Pasadena, Calif. Portland, Oreg. Sacramento, Ca San Diego, Calif. San Francisco, C San Jose, Calif. Santa Cruz, Cali Seattle, Wash. Tacoma, Wash. TOTAL	130 1,850 15 89 if. 79 lif. 470 35 151 161 163 ℃ 167 Calif. 123 184 f. 422 122	138 25 97 19 1,284 100 65 14 44 46 51 332 24 101 102 111 82 23 33 68 7,244	39 2 40 2 19 4 365 2 16 3 13 17 8 8 41 365 2 33 9 2 8 9 2,114	16 21 6 6 123 1 4 2 9 34 2 7 15 7 5 7 54	3 1 9 - 2 3 48 - 3 - 1 2 11 1 - 9 2 6 5 4 3 4 1 1 2 6 5	4 1 5 - 4 1 29 2 2 1 - 1 - 5 - 5 - 2 2 1 4 3 5 - 3 2 2 - 207 207	12 4 15 1 11 10 126 4 - 2 8 25 3 13 8 4 18 13 5 6 5 2 685

TABLE IV. Deaths in 122 U.S. cities,* week endingSeptember 29, 2001 (39th Week)

U: Unavailable. * Mortality data

: Unavailable. -: No reported cases. Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of \geq 100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. Pneumonia and influenza. t

Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.
 Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H. Wayne S. Brathwaite

State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Jim Vaughan Carol A. Worsham **CDC Operations Team** Carol M. Knowles Deborah A. Adams Willie J. Anderson Lateka M. Dammond Patsy A. Hall Mechele A. Hester Felicia J. Connor Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D. Michele D. Renshaw Eri

Erica R. Shaver

All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr/>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at ftp://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson						
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins						
☆U.S. Government Printing Office: 2002-733-100/49014 Region IV								